Full Press Release Details
Enochian BioSciences
Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience
Los Angeles. April 20,2022. Enochian
BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases
and cancer, today is announcing the appointment of Dr. Fran ois Binette, Ph.D. as Executive Vice President for Research and Development.
Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior
VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery
to clinical stages and contributed to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over
$650 million in upfront and milestone payments. He previously held positions at Johnson and Johnson, where he led several innovative regenerative
medicine combination product development initiatives from discovery to approved clinical trials in the US and Europe, and at Medtronics,
developing biologics, active devices, and combination products.
"Enochian is very excited that Dr. Binette will be leading Research
and Development. His broad expertise in Big Pharma and BioTech in driving pipeline and product development for innovative therapies to
ensure swift transition, comes at a perfect time for the trajectory of the Company and for the development of our pipeline toward key
regulatory and clinical milestones," said Dr. Mark Dybul, Enochian's CEO.
"My entire professional career
has focused on advancing new therapeutic modalities to provide definitive curative therapies to diseases with little to no treatment options.
I was struck with the breakthrough innovation paving the way toward potential cures for many diseases that Enochian is spearheading, and
feel privilege to be part of it," Francois said.